SSB
NBSE

Sandy Spring Bank’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Sandy Spring Bank’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25
Closed -$4K – 998
2020
Q2 		$4K Hold
25
– – ﹤0.01% 789
2020
Q1 		$4K Hold
25
– – ﹤0.01% 789
2019
Q4 		$4K Hold
25
– – ﹤0.01% 789
2019
Q3 		$2K Hold
25
– – ﹤0.01% 820
2019
Q2 		$2K Buy
25
+7
+39% +$396 ﹤0.01% 812
2019
Q1 		$1K Buy
+18
New +$861 ﹤0.01% 771

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sandy Spring Bank's NBSE Position: Q3 2020 in Review

Sandy Spring Bank sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2020, closing a stake of 25 shares — an estimated $4K sold.

Sandy Spring Bank first reported a position in NBSE in Q1 2019 and held it in 6 quarters. The position peaked at $4K in Q2 2020. 50 funds tracked by Wall St. Rank hold NBSE as of Q3 2020.

  • Sandy Spring Bank reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Sandy Spring Bank sold 25 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $4K.
  • Sandy Spring Bank first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2019 and held it in 6 quarters.
  • Sandy Spring Bank's NeuBase Therapeutics, Inc. Common Stock position peaked at $4K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Sandy Spring Bank's 13F filing for Q3 2020, filed 9 Nov 2020.